Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising important questions about durability, safety, and patient selection.
Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune therapies—paired with MRD monitoring and intensified maintenance strategies—is redefining outcomes in mantle cell lymphoma.
Remote patient monitoring can safely enable outpatient bispecific dosing for selected patients, but older or high-risk individuals may still require closer human oversight and structured support.
Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug resistance in mantle cell lymphoma through epigenetic profiling and the biology of drug-tolerant persister cells.
Combining complementary targeted therapies for multiple myeloma has shown impressive efficacy, but safety, quality of life, and costs must also be considered.
Data suggest that remote patient monitoring may support outpatient step-up dosing of bispecific antibodies by enabling earlier CRS detection.
Experts discuss the current status of neoadjuvant ADC therapies, eligibility criteria, and future treatment pathways for high-risk patients.
Discover the latest insights on Zongertinib's efficacy and safety for HER2-mutant non-small cell lung cancer, promising new treatment options.
Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors.
Explore the differences between emerging HER2-targeted TKIs, Zongertinib and Seviberatinib, and their therapeutic implications in cancer treatment.
Real-world evidence highlights the effectiveness of teclistamab and elranatamab in treating frail multiple myeloma patients, paving the way for future therapies.
Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting efficacy and safety.
Panelists discuss how collaboration, innovation, and stigma reduction are key to transforming schizophrenia care.
Panelists discuss how addressing payer restrictions and leveraging data-driven advocacy are essential for timely access to care.
Clascoterone cream 1% plus adapalene gel 0.3% offers an effective, well-tolerated topical option for moderate to severe acne, with combination therapy enhancing adherence and outcomes.
Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.
Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.
Standardized monitoring workflows and clearer reimbursement support are critical to improving community clinicians’ readiness to deliver bispecific antibodies safely in the outpatient setting.
ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.
Teclistamab plus daratumumab delivers unprecedented progression-free survival benefits over standard of care in relapsed/refractory multiple myeloma, while raising important questions about how best to sequence bispecific combinations with CAR T-cell therapy.
While earlier-line BCMA CAR T-cell therapy in multiple myeloma offers superior efficacy and longer treatment-free survival, careful monitoring and further research are needed to manage rare but serious toxicities.
ATALANTA-1 data presented at ASH 2025 showed remarkable response rates and rapid manufacturing with an investigational autologous CAR T-cell therapy.
While implementing bispecific antibodies in community oncology carries a steep learning curve, targeted education and stronger multidisciplinary collaboration can significantly improve clinician confidence and real-world uptake.
Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for those with HER2 mutations.
Explore the evolving treatments for IgA nephropathy, highlighting the shift towards proactive strategies and the role of Nefecon in patient care.
Explore the latest strategies for selecting treatment regimens in HER2-positive breast cancer, focusing on safety and patient-specific factors.
Steven Stoner, PharmD, advises managed care teams to use rigorous diagnostic assessments, monitor adherence, and invest heavily in early patient follow-up to accurately attribute costs to treatment-resistant depression.
Explore the latest findings from the KATHERINE, PATINA, and HER2CLIMB-05 trials, highlighting advancements and challenges in breast cancer treatment.
Steven Stoner, PharmD, advocates for integrating patient-reported outcomes and digital monitoring to identify early treatment failure and justify utilizing highly effective therapies like dextromethorphan-bupropion sooner.
Explore the unique mechanisms of bispecific antibodies and their rapid availability compared to CAR T-cell therapies in cancer treatment.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
